Erin Wilson
Stock Analyst at Morgan Stanley
(1.83)
# 2,935
Out of 4,789 analysts
20
Total ratings
46.15%
Success rate
0.75%
Average return
Main Sectors:
Stocks Rated by Erin Wilson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RPD Rapid7 | Maintains: Equal-Weight | $38 → $33 | $26.78 | +23.23% | 5 | Mar 18, 2025 | |
| ALGN Align Technology | Maintains: Outperform | $715 → $732 | $158.08 | +363.06% | 3 | Jul 29, 2021 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $352 → $385 | $145.99 | +163.72% | 1 | Jul 20, 2021 | |
| IQV IQVIA Holdings | Maintains: Outperform | $242 → $265 | $171.24 | +54.75% | 1 | Jul 20, 2021 | |
| MEDP Medpace Holdings | Maintains: Outperform | $200 → $205 | $297.73 | -31.15% | 1 | Jul 20, 2021 | |
| ICLR ICON Public Limited Company | Maintains: Outperform | $245 → $250 | $166.56 | +50.10% | 2 | Jul 20, 2021 | |
| ELAN Elanco Animal Health | Upgrades: Outperform | $33 → $38 | $10.35 | +267.15% | 1 | Feb 26, 2021 | |
| FLGT Fulgent Genetics | Downgrades: Underperform | n/a | $17.31 | - | 1 | Jan 8, 2021 | |
| TMO Thermo Fisher Scientific | Initiates: Neutral | $341 | $482.97 | -29.40% | 1 | Jan 22, 2020 | |
| INCR InterCure | Maintains: Outperform | $68 → $54 | $1.37 | +3,841.61% | 4 | Nov 14, 2017 |
Rapid7
Mar 18, 2025
Maintains: Equal-Weight
Price Target: $38 → $33
Current: $26.78
Upside: +23.23%
Align Technology
Jul 29, 2021
Maintains: Outperform
Price Target: $715 → $732
Current: $158.08
Upside: +363.06%
Charles River Laboratories International
Jul 20, 2021
Maintains: Neutral
Price Target: $352 → $385
Current: $145.99
Upside: +163.72%
IQVIA Holdings
Jul 20, 2021
Maintains: Outperform
Price Target: $242 → $265
Current: $171.24
Upside: +54.75%
Medpace Holdings
Jul 20, 2021
Maintains: Outperform
Price Target: $200 → $205
Current: $297.73
Upside: -31.15%
ICON Public Limited Company
Jul 20, 2021
Maintains: Outperform
Price Target: $245 → $250
Current: $166.56
Upside: +50.10%
Elanco Animal Health
Feb 26, 2021
Upgrades: Outperform
Price Target: $33 → $38
Current: $10.35
Upside: +267.15%
Fulgent Genetics
Jan 8, 2021
Downgrades: Underperform
Price Target: n/a
Current: $17.31
Upside: -
Thermo Fisher Scientific
Jan 22, 2020
Initiates: Neutral
Price Target: $341
Current: $482.97
Upside: -29.40%
InterCure
Nov 14, 2017
Maintains: Outperform
Price Target: $68 → $54
Current: $1.37
Upside: +3,841.61%